A bill to amend the Public Health Service Act to authorize a scholarship and loan repayment program to incentivize physicians to enter into the field of sickle cell disease research, treatment, and patient care, and for other purposes.

On September 23, 2026, Sen. Chris Van Hollen (D-MD) introduced S5489, a bill to amend the Public Health Service Act to create a scholarship and loan repayment program aimed at increasing the number of physicians entering the field of sickle cell disease research, treatment, and patient care. The bill has been read twice and referred to the Committee on Health, Education, Labor, and Pensions. It currently has two cosponsors: Sens. Cory Booker (D-NJ) and Amy Klobuchar (D-MN). The bill is in an early stage with no committee hearings or markup scheduled. No specific funding amount is authorized in the bill text; any future funding would require a separate appropriations process. The legislation does not name specific companies or create direct revenue streams for publicly traded entities. The primary beneficiaries would be academic medical centers and research institutions, which are largely non-profit or private entities not publicly traded. While sickle cell disease treatments are a growing area for biopharma companies like Vertex Pharmaceuticals ($VRTX) and Bluebird Bio ($BLUE), this bill focuses on physician workforce development rather than drug development or reimbursement. No direct causal chain can be established to any publicly traded company with sufficient confidence. The bill's early stage and lack of specific funding mechanism limit its near-term market impact.